Clinical Trial: Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Trial of Gleevec (STI571) in Therapy of Ewing's Family of Tumors and Desmoplastic Small Round Cell Tumors
Brief Summary:
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.
Detailed Summary:
OBJECTIVES:
- Determine the effectiveness of imatinib mesylate in patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.
- Determine the toxic effects of this drug in these patients.
- Determine the duration of disease-free and overall survival of patients treated with this drug.
OUTLINE: This is an open-label study.
Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Sponsor: City of Hope Medical Center
Current Primary Outcome: Response rate as measured by RECIST criteria
Original Primary Outcome:
Current Secondary Outcome: Progression-free survival at 6 months
Original Secondary Outcome:
Information By: City of Hope Medical Center
Dates:
Date Received: June 5, 2003
Date Started: June 2002
Date Completion:
Last Updated: February 5, 2010
Last Verified: February 2010
